Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

384 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study.
Baudry E, Naoun N, Auclin E, Saldana C, Barthelemy P, Geoffrois L, Thibault C, de Vries-Brilland M, Borchiellini D, Maillet D, Hirsch L, Vauchier C, Carril-Ajuria L, Colomba E, Bernard-Tessier A, Escudier B, Flippot R, Albigès L. Baudry E, et al. Among authors: barthelemy p. Eur J Cancer. 2023 Nov;193:113292. doi: 10.1016/j.ejca.2023.113292. Epub 2023 Aug 18. Eur J Cancer. 2023. PMID: 37717282
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, Banek S, Guadalupi V, Ku JH, Valderrama BP, Tran B, Triantos S, Kean Y, Akapame S, Deprince K, Mukhopadhyay S, Stone NL, Siefker-Radtke AO; THOR Cohort 1 Investigators. Loriot Y, et al. N Engl J Med. 2023 Nov 23;389(21):1961-1971. doi: 10.1056/NEJMoa2308849. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870920 Clinical Trial.
Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma.
Davidson G, Helleux A, Vano YA, Lindner V, Fattori A, Cerciat M, Elaidi RT, Verkarre V, Sun CM, Chevreau C, Bennamoun M, Lang H, Tricard T, Fridman WH, Sautes-Fridman C, Su X, Plassard D, Keime C, Thibault-Carpentier C, Barthelemy P, Oudard SM, Davidson I, Malouf GG. Davidson G, et al. Among authors: barthelemy p. Cancer Res. 2023 Sep 1;83(17):2952-2969. doi: 10.1158/0008-5472.CAN-22-3034. Cancer Res. 2023. PMID: 37335139
Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG-AFU 26 NIVOREN.
Guilhem-Ducléon G, Dalban C, Negrier S, Gravis G, Laguerre B, Chevreau C, Oudard S, Barthelemy P, Ladoire S, Boughalem E, Borchiellini D, Linassier C, Nenan S, Flippot R, Albiges L, Goupil MG. Guilhem-Ducléon G, et al. Among authors: barthelemy p. Clin Genitourin Cancer. 2023 Dec;21(6):643-652. doi: 10.1016/j.clgc.2023.07.008. Epub 2023 Jul 20. Clin Genitourin Cancer. 2023. PMID: 37635052
Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial.
Billon E, Dalban C, Oudard S, Chevreau C, Laguerre B, Barthélémy P, Borchiellini D, Geoffrois L, Negrier S, Joly F, Thiery-Vuillemin A, Gross-Goupil M, Rolland F, Priou F, Mahammedi H, Tantot F, Escudier B, Chabaud S, Albiges L, Gravis G. Billon E, et al. Among authors: barthelemy p. Eur Urol Oncol. 2023 Oct 7:S2588-9311(23)00200-6. doi: 10.1016/j.euo.2023.09.009. Online ahead of print. Eur Urol Oncol. 2023. PMID: 37813745
Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas.
Lu X, Vano YA, Su X, Helleux A, Lindner V, Mouawad R, Spano JP, Rouprêt M, Compérat E, Verkarre V, Sun CM, Bennamoun M, Lang H, Barthelemy P, Cheng W, Xu L, Davidson I, Yan F, Fridman WH, Sautes-Fridman C, Oudard S, Malouf GG. Lu X, et al. Among authors: barthelemy p. Cell Rep Med. 2023 Nov 21;4(11):101287. doi: 10.1016/j.xcrm.2023.101287. Epub 2023 Nov 14. Cell Rep Med. 2023. PMID: 37967556 Free PMC article.
Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status.
Carril-Ajuria L, Colomba E, Romero-Ferreiro C, Cerbone L, Ratta R, Barthelemy P, Vindry C, Fléchon A, Cherifi F, Boughalem E, Linassier C, Fornarini G, Rebuzzi SE, Gross-Goupil M, Saldana C, Martin-Soberón M, de Velasco G, Manneh R, Pernaut C, Sanchez de Torre A, Flippot R, Escudier B, Albiges L. Carril-Ajuria L, et al. Among authors: barthelemy p. Eur J Cancer. 2023 Feb;180:21-29. doi: 10.1016/j.ejca.2022.11.013. Epub 2022 Nov 26. Eur J Cancer. 2023. PMID: 36527973
Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.
Velev M, Dalban C, Chevreau C, Gravis G, Negrier S, Laguerre B, Gross-Goupil M, Ladoire S, Borchiellini D, Geoffrois L, Joly F, Priou F, Barthelemy P, Laramas M, Narciso B, Thiery-Vuillemin A, Berdah JF, Ferrari V, Dominique Thomas Q, Mione C, Curcio H, Oudard S, Tantot F, Escudier B, Chabaud S, Albiges L, Thibault C. Velev M, et al. Among authors: barthelemy p. Eur J Cancer. 2023 Mar;182:66-76. doi: 10.1016/j.ejca.2022.12.028. Epub 2023 Jan 13. Eur J Cancer. 2023. PMID: 36746010 Clinical Trial.
384 results